Exelixis Releases Fruit Fly Stocks

South San Francisco-based Exelixis has released nearly 18,000 strains of Drosophila melanogaster to the academic community. The collection is part of a larger assembly of 29,000 strains created by transposon insertion, and it represents, according to an editorial accompanying the release, "what may be the largest public release of scientific material in history."123"We had many long discussions within the company about how best to further develop the technology, and in the end we decided to rele

Written bySam Jaffe
| 1 min read

Register for free to listen to this article
Listen with Speechify
0:00
1:00
Share

South San Francisco-based Exelixis has released nearly 18,000 strains of Drosophila melanogaster to the academic community. The collection is part of a larger assembly of 29,000 strains created by transposon insertion, and it represents, according to an editorial accompanying the release, "what may be the largest public release of scientific material in history."123

"We had many long discussions within the company about how best to further develop the technology, and in the end we decided to release it for everyone in academia to use," says Greg Plowman, senior vice president of research at Exelixis. Researchers at for-profit firms, though, must still license the technology.

The strains, representing about half of all known fly genes, will be split between Indiana University's Drosophila Stock Center in Bloomington http://flystocks.bio.indiana.edu and the Department of Cell Biology at Harvard Medical School (contact drosophila@hms.harvard.edu). "It's exciting because it can take up to a year for me ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies